Agios Pharmaceuticals, Inc. (AGIO)
AGIONASDAQ-GSBiotechnology: Pharmaceutical Preparations
$31.14
-0.2400 (-0.76%) today
Regular session, Nov 10, 2:44 PM ET
- Market cap
- $1.86bn
- P/E
- –
- EPS, last 4 quarters
- $-6.32
- Dividend yield
- –
- Day range
- $30.47 to $31.58
- 52-week range
- $22.24 to $46.00
- Average volume
- 1.14m
- Previous close
- $31.38
Analysts
6 coveringBuy4 buy, 2 hold, 0 sell
Targets a year out average $45.80, +47.1% from here
Earnings
next estimate $-1.24Next report
Dec 2025
+6.1%
Mar 2026
+6.6%
Jun 2026
+9.1%
Sep 2026
+17.4%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $19.97m | $20.75m | $44.74m | $55.38m |
| Gross profit | $18.09m | $19.43m | $41.75m | $52.86m |
| Operating income | -$121.58m | -$110.03m | -$110.55m | -$77.16m |
| Net income | -$108.04m | -$99.11m | -$100.70m | -$65.05m |
Last four quarters: revenue $140.84m, margin -264.8%, free cash flow -$335.97m
News
8 latest- Weekly Buzz: RDY, LUPIN, SUNPHARMA Score FDA Wins; AGIO, RARE Slash Jobs; CVS Plots Split RTTNews · 4 days ago
- Agios (AGIO) Q3 2026 Earnings Call TranscriptThe Motley Fool · 5 days ago
- Agios Q3 Mitapivat Revenue Surges More Than Fourfold; Sickle Cell FDA Decision Set For February 2027 RTTNews · 5 days ago
- What Agios Pharmaceuticals (AGIO) Said on Its Q3 Earnings CallMarketBeat · 5 days ago
- Agios Pharmaceuticals, Inc. Reports Third Quarter 2026 Net Product Revenue of $55.4 million and Extension of Mitapivat PDUFA Date to February 1, 2027Fintel · 5 days ago
- Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Beats Revenue EstimatesZacks · 5 days ago
- IDEAYA Biosciences, Inc. (IDYA) Reports Q3 Loss, Tops Revenue EstimatesZacks · Nov 3, 2026
- FDA Extends Agios' Mitapivat Sickle Cell Disease Review; New PDUFA Date Set; Stock Down RTTNews · Oct 30, 2026
The company
At Agios, our vision is to redefine the future of rare disease treatment. Fueled by connections, we build trusted partnerships with communities - collaborating to develop and deliver innovative medicines that have the potential to transform lives. With a foundation in hematology, we combine biological expertise with real-world insights to advance a growing pipeline of rare disease medicines that reflect the priorities of the people we serve. Agios is a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- agios.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.